{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:11:27Z","timestamp":1767982287567,"version":"3.49.0"},"reference-count":93,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The mammalian target of rapamycin (mTOR) has a crucial role in carcinogenesis, angiogenesis, cellular proliferation, and metastasis; however, its significance in non-small cell lung cancer (NSCLC) remains contentious. Consequently, this study aims to assess the clinicopathological and prognostic importance of mTOR\/p-mTOR expression in NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Literature retrieval was undertaken by searching English databases PubMed, EMBASE, Web of Science, and Cochrane Library as well as Chinese databases CNKI, Wan Fang, and VIP for full-text publications that satisfied our eligibility criteria up to November 2021. STATA 12.0 was used to conduct statistical analysis (STATA Corporation, College Station, TX).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This meta-analysis includes a total of 4683 patients from 28 primary publications. mTOR\/p-mTOR expression was associated with sex (OR\u2005=\u20050.608, 95% CI: 0.442\u20130.836), lymph node metastasis (OR\u2005=\u20052.084, 95% CI: 1.437\u20133.182), and CEA (OR\u2005=\u20051.584, 95% CI: 1.135\u20132.209), but not with age, histological type, depth of tumor invasion, distant metastasis, TNM stage, differentiation degree, tumor size, or smoking. In addition, the expression of mTOR\/p-mTOR is related to shorter overall survival in NSCLC patients (HR\u2005=\u20051.415, 95% CI: 1.051\u20131.905).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Positive mTOR\/p-mTOR expression was substantially correlated with unfavorable conditions on the sex, lymph node metastases, and CEA levels. mTOR\/p-mTOR may indicate a bad prognosis for NSCLC. The current findings must be confirmed and changed by other high-quality research employing a multivariate analysis on bigger sample size.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032340","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T14:05:06Z","timestamp":1672149906000},"page":"e32340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0117-7070","authenticated-orcid":false,"given":"Weiwei","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China"},{"name":"Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin."},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants.","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","article-title":"Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.","volume":"18","author":"Oudkerk","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors.","volume":"16","author":"Memmott","year":"2021","journal-title":"J Thorac Oncol."},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies.","volume":"40","author":"Passaro","year":"2022","journal-title":"J Clin Oncol."},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer.","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-020-1138-4","article-title":"Autophagy and autophagy-related proteins in cancer.","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/cells8010018","article-title":"mTOR: a cellular regulator interface in health and disease.","volume":"8","author":"Boutouja","year":"2019","journal-title":"Cells"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth.","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/ijms22041743","article-title":"The role of mTOR signaling as a therapeutic target in cancer.","volume":"22","author":"Popova","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"109746","DOI":"10.1016\/j.biopha.2019.109746","article-title":"Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.","volume":"125","author":"Wu","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours.","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Biosci."},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC).","volume":"11","author":"Tan","year":"2020","journal-title":"Thor Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"701464","DOI":"10.1155\/2009\/701464","article-title":"A comprehensive review of immunosuppression used for liver transplantation.","volume":"2009","author":"Mukherjee","year":"2009","journal-title":"J Transplant"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"67521","DOI":"10.18632\/oncotarget.11750","article-title":"Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study.","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, andomized, double-blind, placebo-controlled trial.","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet."},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet."},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdp060","article-title":"Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.","volume":"20","author":"Soria","year":"2009","journal-title":"Ann Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26409","article-title":"A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.","volume":"64","author":"Becher","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors.","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-019-0050-0","article-title":"Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells.","volume":"4","author":"Nepstad","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1758835920940939","DOI":"10.1177\/1758835920940939","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer.","volume":"12","author":"du Rusquec","year":"2020","journal-title":"Ther Adv Med Oncol."},{"key":"R27-20250504","first-page":"476","article-title":"Mammalian target of rapamycin: a central node of complex signaling cascades.","volume":"4","author":"Dobashi","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.humpath.2010.07.021","article-title":"Mammalian target of rapamycin regulates expression of beta-catenin in hepatocellular carcinoma.","volume":"42","author":"Feng","year":"2011","journal-title":"Hum Pathol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/leu.2008.395","article-title":"The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia.","volume":"23","author":"Gallay","year":"2009","journal-title":"Leukemia"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","article-title":"Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.","volume":"108","author":"Kornblau","year":"2006","journal-title":"Blood"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-016-2940-7","article-title":"Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.","volume":"16","author":"Li","year":"2016","journal-title":"BMC Cancer"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/modpathol.3800525","article-title":"The Akt pathway in human breast cancer: a tissue-array-based analysis.","volume":"19","author":"Bose","year":"2006","journal-title":"Mod Pathol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"e21138","DOI":"10.1097\/MD.0000000000021138","article-title":"A systematic review and meta-analysis protocol of clinical characteristics and prognostic significance of mammalian target of rapamycin for gastric cancer patients.","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2174\/1574892816666211130170149","article-title":"Prognostic and therapeutic values of autophagy-related genes in triple-negative breast cancer.","volume":"17","author":"Liu","year":"2021","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"153655","DOI":"10.1016\/j.prp.2021.153655","article-title":"MTOR\/4EBP1 signaling and MMR status in colorectal cancer: new correlations and arising perspectives.","volume":"228","author":"Zouki","year":"2021","journal-title":"Pathol Res Pract"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.4081\/ejh.2021.3304","article-title":"Correlation of the AKT\/mTOR signaling pathway with the clinicopathological features and prognosis of nasopharyngeal carcinoma.","volume":"65","author":"Wang","year":"2021","journal-title":"Eur J Histochem."},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3892\/ol.2015.3228","article-title":"Expression and clinical significance of mammalian target of rapamycin\/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue.","volume":"10","author":"Lu","year":"2015","journal-title":"Oncol Lett"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6602902","article-title":"mTOR signaling: implications for cancer and anticancer therapy.","volume":"94","author":"Petroulakis","year":"2006","journal-title":"Br J Cancer"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.humpath.2010.05.025","article-title":"Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor\/Akt in human lung carcinomas.","volume":"42","author":"Dobashi","year":"2011","journal-title":"Hum Pathol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.23996","article-title":"Critical and diverse involvement of Akt\/mammalian target of rapamycin signaling in human lung carcinomas.","volume":"115","author":"Dobashi","year":"2009","journal-title":"Cancer"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism.","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/CMR.0000000000000780","article-title":"Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis.","volume":"31","author":"Chen","year":"2021","journal-title":"Melanoma Res"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.3934\/mbe.2019340","article-title":"Expression of autophagy-related factor p62 for lung cancer diagnosis and prognosis: a systematic review and meta-analysis.","volume":"16","author":"Wang","year":"2019","journal-title":"Math Biosci Eng."},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jep.12889","article-title":"Critical appraisal of nonrandomized studies \u2013 a review of recommended and commonly used tools.","volume":"25","author":"Quigley","year":"2019","journal-title":"J Eval Clin Pract"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4310\/SII.2020.v13.n4.a3","article-title":"Statistical methods for quantifying between-study heterogeneity in meta-analysis with focus on rare binary events.","volume":"13","author":"Zhang","year":"2020","journal-title":"Stat Interface."},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"e15987e15987","DOI":"10.1097\/MD.0000000000015987","article-title":"The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses.","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1369\/0022155414523022","article-title":"Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.","volume":"62","author":"Kitano","year":"2014","journal-title":"J Histochem Cytochem"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"1758835920953731","DOI":"10.1177\/1758835920953731","article-title":"EGFR\/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer.","volume":"12","author":"Crees","year":"2020","journal-title":"Ther Adv Med Oncol."},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"e0227768","DOI":"10.1371\/journal.pone.0227768","article-title":"Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer.","volume":"15","author":"Lu","year":"2020","journal-title":"PLoS One"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1002\/cncr.25959","article-title":"Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.","volume":"117","author":"Liu","year":"2011","journal-title":"Cancer"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.7314\/APJCP.2013.14.6.3725","article-title":"Prognostic value of phosphorylated mTOR\/RPS6KB1 in non-small cell lung cancer.","volume":"14","author":"Zhang","year":"2013","journal-title":"Asian Pac J Cancer Prev."},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00428-012-1239-6","article-title":"Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer.","volume":"460","author":"Oh","year":"2012","journal-title":"Virchows Arch."},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00595-011-0028-1","article-title":"mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.","volume":"42","author":"Wang","year":"2012","journal-title":"Surg Today"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000334340","article-title":"Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.","volume":"79","author":"Kim","year":"2012","journal-title":"Pathobiology."},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1158\/1078-0432.CCR-09-0099","article-title":"High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma.","volume":"15","author":"Anagnostou","year":"2009","journal-title":"Clin Cancer Res."},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/JTO.0b013e3181ce6604","article-title":"Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.","volume":"5","author":"Dhillon","year":"2010","journal-title":"J Thor Oncol."},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2011.06.012","article-title":"Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.","volume":"75","author":"Gately","year":"2012","journal-title":"Lung Cancer."},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.lungcan.2015.04.003","article-title":"Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.","volume":"89","author":"Shin","year":"2015","journal-title":"Lung Cancer."},{"key":"R63-20250504","first-page":"536","article-title":"\u81ea\u566c\u76f8\u5173\u86cb\u767d\u5728\u80ba\u9cde\u764c\u548c\u817a\u764c\u7ec4\u7ec7\u4e2d\u7684\u8868\u8fbe\u53ca\u76f8\u5173\u6027\u7814\u7a76. [J].","volume":"42","year":"2014","journal-title":"\u5929\u6d25\u533b\u836f"},{"key":"R64-20250504","first-page":"354","article-title":"p-mTOR\u5728\u2160\uff5eIII\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec4\u7ec7\u4e2d\u7684\u8868\u8fbe\u53ca\u5176\u4e0e\u9884\u540e\u7684\u5173\u7cfb.","volume":"5","year":"2008","journal-title":"\u4e2d\u56fd\u547c\u5438\u4e0e\u5371\u91cd\u76d1\u62a4\u6742\u5fd7"},{"key":"R65-20250504","article-title":"\u81ea\u566c\u6807\u8bb0\u86cb\u767d (Beclin1\u3001LC3\u3001p62\u3001mTOR)\u5728\u6076\u6027\u80ba\u7ed3\u8282\u4e2d\u7684\u8868\u8fbe\u53ca\u4e34\u5e8a\u610f\u4e49 [40].","year":"2021","journal-title":"\u897f\u5317\u6c11\u65cf\u5927\u5b66"},{"key":"R66-20250504","first-page":"710","article-title":"\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec4\u7ec7PTEN\u3001p-Akt\u53cap-mTOR\u7684\u8868\u8fbe\u53ca\u610f\u4e49.","volume":"39","year":"2018","journal-title":"\u5e7f\u4e1c\u533b\u5b66"},{"key":"R67-20250504","first-page":"354","article-title":"STAT3, mTOR, ERK1\/2\u78f7\u9178\u5316\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e2d\u7684\u8868\u8fbe.","volume":"36","year":"2016","journal-title":"\u4e2d\u56fd\u8001\u5e74\u5b66\u6742\u5fd7"},{"key":"R68-20250504","first-page":"41","article-title":"\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec4\u7ec7\u4e2dCCR7\u3001mTOR\u8868\u8fbe\u53d8\u5316\u53ca\u610f\u4e49.","volume":"53","year":"2013","journal-title":"\u5c71\u4e1c\u533b\u836f"},{"key":"R69-20250504","first-page":"602","article-title":"PTEN\u548cmTOR\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e2d\u7684\u8868\u8fbe\u53ca\u610f\u4e49.","volume":"49","year":"2018","journal-title":"\u5c71\u897f\u533b\u79d1\u5927\u5b66\u5b66\u62a5"},{"key":"R70-20250504","article-title":"mTOR\u53caelF4E\u5728\u2160a\u671f\uff5eIIIa\u671f\u80ba\u9cde\u764c\u7ec4\u7ec7\u4e2d\u7684\u8868\u8fbe\u53ca\u4e34\u5e8a\u610f\u4e49 [45].","year":"2010","journal-title":"\u90d1\u5dde\u5927\u5b66"},{"key":"R71-20250504","article-title":"mTOR\u4fe1\u53f7\u901a\u8def\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec4\u7ec7\u7684\u8868\u8fbe\u4e0e\u9884\u540e\u7684\u5173\u7cfb [46].","year":"2019","journal-title":"\u6e29\u5dde\u533b\u79d1\u5927\u5b66"},{"key":"R72-20250504","first-page":"1689","article-title":"mTOR\u4fe1\u53f7\u901a\u8def\u76f8\u5173\u5206\u5b50\u5728\u80ba\u9cde\u764c\u7ec4\u7ec7\u4e2d\u8868\u8fbe\u7684\u610f\u4e49.","volume":"42","year":"2020","journal-title":"\u6d59\u6c5f\u533b\u5b66"},{"key":"R73-20250504","first-page":"46","article-title":"\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec4\u7ec7p-mTOR\u3001p70s6k\u3001PTEN\u86cb\u767d\u7684\u8868\u8fbe\u53d8\u5316\u53ca\u5176\u610f\u4e49.","volume":"58","year":"2018","journal-title":"\u5c71\u4e1c\u533b\u836f"},{"key":"R74-20250504","article-title":"CHI3L1\u548cPI3K\/AKT\/mTOR\u4fe1\u53f7\u901a\u8def\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ec6\u80de\u7684\u8868\u8fbe\u53ca\u5176\u610f\u4e49 [49].","year":"2017","journal-title":"\u6cf0\u5c71\u533b\u5b66\u9662"},{"key":"R75-20250504","first-page":"895","article-title":"\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e2dp-mTOR\u3001Beclin1\u53caLC3\u86cb\u767d\u7684\u8868\u8fbe\u53ca\u610f\u4e49.","volume":"40","year":"2019","journal-title":"[J]. \u5e7f\u4e1c\u533b\u5b66"},{"key":"R76-20250504","first-page":"155","article-title":"p62\u548cmTOR\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4e2d\u7684\u8868\u8fbe\u53ca\u4e34\u5e8a\u610f\u4e49.","volume":"24","year":"2020","journal-title":"\u57fa\u5c42\u533b\u5b66\u8bba\u575b"},{"key":"R77-20250504","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-09-0986","article-title":"Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.","volume":"16","author":"Yoshizawa","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R78-20250504","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/bjc.2014.88","article-title":"ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.","volume":"110","author":"Shimizu","year":"2014","journal-title":"Br J Cancer"},{"key":"R79-20250504","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1158\/1078-0432.CCR-13-1959","article-title":"Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy.","volume":"20","author":"Gold","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R80-20250504","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1074\/jbc.M113.536854","article-title":"A Complex between Atg7 and Caspase-9: a novel mechanism of cross-regulation between autophagy and apoptosis.","volume":"289","author":"Han","year":"2014","journal-title":"J Biol Chem"},{"key":"R81-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"mTOR: a pharmacologic target for autophagy regulation.","volume":"125","author":"Kim","year":"2015","journal-title":"J Clin Invest"},{"key":"R82-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol Cell"},{"key":"R83-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/ijms18020367","article-title":"Role of autophagy and apoptosis in non-small-cell lung cancer.","volume":"18","author":"Liu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R84-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB.","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"R85-20250504","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1039\/C5MB00101C","article-title":"The PI3K\/AKT\/mTOR interactive pathway.","volume":"11","author":"Ersahin","year":"2015","journal-title":"Mol Biosyst"},{"key":"R86-20250504","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4161\/cc.10.13.16244","article-title":"LKB1\/AMPK\/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.","volume":"10","author":"Green","year":"2011","journal-title":"Cell Cycle."},{"key":"R87-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer.","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int"},{"key":"R88-20250504","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR.","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"R89-20250504","first-page":"1689","article-title":"mTOR\u4fe1\u53f7\u901a\u8def\u76f8\u5173\u5206\u5b50\u5728\u80ba\u9cde\u764c\u7ec4\u7ec7\u4e2d\u8868\u8fbe\u7684\u610f\u4e49.","volume":"42","year":"2020","journal-title":"\u6d59\u6c5f\u533b\u5b66"},{"key":"R90-20250504","doi-asserted-by":"crossref","first-page":"e0170302","DOI":"10.1371\/journal.pone.0170302","article-title":"P-mTOR expression and implication in breast carcinoma: a systematic review and meta-analysis.","volume":"12","author":"Ding","year":"2017","journal-title":"PLoS One"},{"key":"R91-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jop.12390","article-title":"mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis.","volume":"45","author":"Marques","year":"2016","journal-title":"J Oral Pathol Med"},{"key":"R92-20250504","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1756-9966-28-152","article-title":"The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray.","volume":"28","author":"Xiao","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"R93-20250504","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/bmm.15.68","article-title":"Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"9","author":"Ooft","year":"2015","journal-title":"Biomark Med"},{"key":"R94-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:23:29Z","timestamp":1746336209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":93,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032340","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}